869299-07-0

Basic information

• Product Name: ethyl 4-oxopyrido[2,3-d][1,3]oxazine-2-carboxylate
• Synonyms: Ethyl 4-oxo-4H-pyrido[2,3-d][1,3]oxazine-2-carboxylate
• CAS NO: 869299-07-0
• Molecular Formula: C₁₀H₈N₂O₄
• Molecular Weight: 220.1815
• Mol File: 869299-07-0.mol

Chemical Properties

• Boiling Point: 373.004°C at 760 mmHg
• Flash Point: 179.387°C
• Density: 1.442g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.624
• CAS DataBase Reference: ethyl 4-oxopyrido[2,3-d][1,3]oxazine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-oxopyrido[2,3-d][1,3]oxazine-2-carboxylate(869299-07-0)
• EPA Substance Registry System: ethyl 4-oxopyrido[2,3-d][1,3]oxazine-2-carboxylate(869299-07-0)

Safety Data

• Hazardous Substances Data: 869299-07-0(Hazardous Substances Data)

Upstream product

• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 4755-77-5 Ethyl oxalyl chloride 

Downstream Products

• 55149-36-5 ethyl 4-oxo-3,4-dihydropyrido[2,3-d]pyrimidine-2-carboxylate 

Relevant articles and documents

SUBSTITUTED 2- AMIDOQUINAZOL-4-ONES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

The present invention provides a novel amide derivative having a matrix metalloproteinase inhibitory activity, and useful as a pharmaceutical agent, which is a compound represented by the formula (I) wherein ring A is an optionally substituted, nitrogen containing heterocycle, ring B is an optionally substituted monocyclic homocycle or an optionally substituted monocyclic heterocycle, Z is N or NR1 (R1 is a hydrogen atom or an optionally substituted hydrocarbon group), is a single bond or a double bond, R2 is a hydrogen atom or an optionally substituted hydrocarbon group, X is an optionally substituted spacer having 1 to 6 atoms, ring C is (1) an optionally substituted homocycle or (2) an optionally substituted heterocycle other than a ring represented by (II) (X′ is S, O, SO, or CH2), and at least one of ring B and ring C has substituent(s), provided that N-{(1S,2R)-1-(3,5-difluorobenzyl)-3-[(3-ethylbenzyl)amino]2 hydroxypropyl}5,6 dimethyl 4 oxo 1,4 dihydrothieno[2,3-d]pyrimidine-2-carboxamide is excluded, or a salt thereof.

Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: Highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site

On the basis of X-ray co-crystal structures of matrix metalloproteinase-13 (MMP-13) in complex with its inhibitors, our structure-based drug design (SBDD) strategy was directed to achieving high affinity through optimal protein-ligand interaction with the unique S1″ hydrophobic specificity pocket. This report details the optimization of lead compound 44 to highly potent and selective MMP-13 inhibitors based on fused pyrimidine scaffolds represented by the thienopyrimidin-4-one 26c. Furthermore, we have examined the release of collagen fragments from bovine nasal cartilage in response to a combination of IL-1 and oncostatin M.